Nashville, TN, United States of America

Zhiguo Bian

USPTO Granted Patents = 9 

 

 

Average Co-Inventor Count = 9.3

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Nashville, TN (US) (2018 - 2020)
  • Lake Bluff, IL (US) (2021 - 2023)

Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Zhiguo Bian: Innovator in Pharmaceutical Chemistry

Introduction

Zhiguo Bian is a prominent inventor based in Nashville, TN (US), known for his significant contributions to pharmaceutical chemistry. He holds a total of 9 patents, focusing on innovative compounds that target critical proteins involved in various diseases, particularly cancer.

Latest Patents

Among his latest patents, one notable invention is the development of substituted indole Mcl-1 inhibitors. This invention provides compounds that inhibit the activity of the anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The invention also includes pharmaceutical compositions and methods for using these compounds to treat diseases characterized by the over-expression or dysregulation of Mcl-1 protein. Another significant patent involves pyrimidines for degrading Bruton's tyrosine kinase, which presents compounds useful as agents in the treatment of chronic lymphocytic leukemia (CLL).

Career Highlights

Zhiguo Bian has worked with esteemed organizations such as Vanderbilt University and AbbVie Inc. His work in these institutions has allowed him to advance his research and contribute to the field of pharmaceutical sciences.

Collaborations

Throughout his career, Bian has collaborated with notable colleagues, including Taekyu Lee and Edward T Olejniczak. These collaborations have further enriched his research and innovation efforts.

Conclusion

Zhiguo Bian's work exemplifies the impact of innovative research in pharmaceutical chemistry. His patents and collaborations continue to pave the way for advancements in treatments for critical health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…